Neurosciences

Neurodegenerative Diseases

Miquel Vila Bover

Summary

In 2015 we have continued our studies on the pathogenicity of α-synuclein and its potential role on neuron dysfunction/death in the context Parkinson’s disease. We have also continued with the development of novel therapeutic tools to interfere with α-synuclein-mediated neurotoxicity. Moreover, in collaboration with other groups of the CIBERNED, we have identified pathological alterations in the epigenetic profile of dopaminergic neurons derived from patients with Parkinson’s disease. These cells were obtained by reprogramming of skin cells into induced pluripotent stem cells and their subsequent differentiation into dopaminergic neurons.

Publications

total

84^.661

impact factor

9^.407

average impact factor

Selected articles+

Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson’s disease patients.
EMBO Mol Med. 2015 Oct 29;7(12):1529-46. doi: 10.15252/emmm.201505439.
PMID: 26516212
Revista:EMBO MOL MED
Referencia:EMBO Mol Med. 2015 Oct 29;7(12):1529-46. doi: 10.15252/emmm.201505439.
Any: 2015
Factor d’impacte: 8,665
Tipus de publicació: Article en revista internacional
Autors: Fernandez-Santiago R, Carballo-Carbajal I, Castellano G, Torrent R, Richaud Y, Sanchez-Danes A, Vilarrasa-Blasi R, Sanchez-Pla A, Mosquera JL, Soriano J, Lopez-Barneo J, Canals JM, Alberch J, Raya A, Vila M, Consiglio A, Martin-Subero JI, Ezquerra M, Tolosa E
DOI: 10.15252/emmm.201505439
Targeting alpha-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations.
Lancet Neurol. 2015 Aug;14(8):855-66. doi: 10.1016/S1474-4422(15)00006-X. Epub 2015 Jun
PMID: 26050140
Revista:LANCET NEUROL
Referencia:Lancet Neurol. 2015 Aug;14(8):855-66. doi: 10.1016/S1474-4422(15)00006-X. Epub 2015 Jun 3.
Any: 2015
Factor d’impacte: 21,896
Tipus de publicació: Article en revista internacional
Autors: Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E, Petsko GA, Meissner WG
DOI: 10.1016/S1474-4422(15)00006-X
Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson’s disease.
Nat Neurosci. 2015 Jun;18(6):826-35. doi: 10.1038/nn.4004. Epub 2015 Apr 27.
PMID: 25915474
Revista:NAT NEUROSCI
Referencia:Nat Neurosci. 2015 Jun;18(6):826-35. doi: 10.1038/nn.4004. Epub 2015 Apr 27.
Any: 2015
Factor d’impacte: 16,095
Tipus de publicació: Article en revista internacional
Autors: Laguna A, Schintu N, Nobre A, Alvarsson A, Volakakis N, Jacobsen JK, Gomez-Galan M, Sopova E, Joodmardi E, Yoshitake T, Deng Q, Kehr J, Ericson J, Svenningsson P, Shupliakov O, Perlmann T
DOI: 10.1038/nn.4004
The Parkinson Disease Mitochondrial Hypothesis: Where Are We at?
Neuroscientist. 2015 Mar 11. pii: 1073858415574600.
PMID: 25761946
Revista:NEUROSCIENTIST
Referencia:Neuroscientist. 2015 Mar 11. pii: 1073858415574600.
Any: 2015
Factor d’impacte: 6,837
Tipus de publicació: Article en revista internacional
Autors: Franco-Iborra S, Vila M, Perier C
DOI: 10.1177/1073858415574600
The Onset of Nonmotor Symptoms in Parkinson’s disease (The ONSET PD Study).
Mov Disord. 2015 Feb;30(2):229-37. doi: 10.1002/mds.26077. Epub 2014 Dec 1.
PMID: 25449044
Revista:MOVEMENT DISORD
Referencia:Mov Disord. 2015 Feb;30(2):229-37. doi: 10.1002/mds.26077. Epub 2014 Dec 1.
Any: 2015
Factor d’impacte: 5,68
Tipus de publicació: Article en revista internacional
Autors: Pont-Sunyer C, Hotter A, Gaig C, Seppi K, Compta Y, Katzenschlager R, Mas N, Hofeneder D, Brucke T, Bayes A, Wenzel K, Infante J, Zach H, Pirker W, Posada IJ, Alvarez R, Ispierto L, De Fabregues O, Callen A, Palasi A, Aguilar M, Marti MJ, Valldeoriola F, Salamero M, Poewe W, Tolosa E
DOI: 10.1002/mds.26077

[ View all publications ]

Main research projects

View+